Atopic Dermatitis

Karl T Clebak; Leesha Helm; Prabhdeep Uppal; Christopher R Davis; Matthew F Helm

doi:10.1016/j.pop.2022.12.004

Atopic Dermatitis

Prim Care. 2023 Jun;50(2):191-203. doi: 10.1016/j.pop.2022.12.004. Epub 2023 Mar 8.

Authors

Karl T Clebak¹, Leesha Helm², Prabhdeep Uppal³, Christopher R Davis², Matthew F Helm⁴

Affiliations

¹ Department of Family and Community Medicine, Penn State Health Milton. S Hershey Medical Center, 500 University Drive, H154/C1613 Hershey, PA 17033, USA. Electronic address: Kclebak@pennstatehealth.psu.edu.
² Department of Family and Community Medicine, Penn State Health Milton. S Hershey Medical Center, 500 University Drive, H154/C1613 Hershey, PA 17033, USA.
³ Department of Family and Community Medicine, ChristianaCare, 1401 Foulk Road, Suite 100B, Wilmington, DE 19803, USA; Department of Emergency Medicine, ChristianaCare, 1401 Foulk Road, Suite 100B, Wilmington, DE 19803, USA.
⁴ Department of Dermatology, Penn State Health Milton. S Hershey Medical Center, 500 University Drive, Suite 4300, MC HU14, Hershey, PA 17033, USA.

PMID: 37105601
DOI: 10.1016/j.pop.2022.12.004

Abstract

Atopic dermatitis (AD) is a common, chronic relapsing, and remitting inflammatory skin disease that is characterized by erythematous, scaly, and pruritic lesions often located over the flexural surfaces. Treatment goals of AD include the reduction of itching and burning, as well as the reduction of skin changes. Treatment of AD includes emollients and skin care, topical therapies including topical corticosteroids and steroid-sparing therapies, systemic therapies, and phototherapy.

Keywords: Atopic dermatitis; Emollients and skin care; Phototherapy; Systemic therapy; Topical therapy.

Publication types

Review

MeSH terms

Dermatitis, Atopic* / drug therapy
Dermatitis, Atopic* / therapy
Emollients / therapeutic use
Glucocorticoids / therapeutic use
Humans
Phototherapy
Skin

Substances

Emollients
Glucocorticoids